We created Archer® Immunoverse™ to characterize the human immune repertoire from RNA input. Immunoverse uses AMP for clonotype identification and frequency reporting. AMP-powered error correction measures sample complexity and enables rare clone identification. The unbiased amplification provides for an accurate and reproducible measure of T cell receptor, or TCR, and B cell receptor, or BCR, diversity.
Immunoverse has applications for both solid tumors and blood cancer, including prognosis and repertoire profiling. It can be used to profile tumor infiltrating lymphocytes and compare TCR diversity in the tumor and in circulation. Immunodiversity can be prognostic and can be used to map neo-antigens derived from cancer cells to the corresponding TCRs. Immunoverse can also measure BCR diversity and look for clonal amplifications indicative of blood cancer.
Archer® Blood Cancer RUO tests detect various driver mutations in hematologic malignancies, such as myeloid and lymphoid diseases, by targeted next-generation sequencing (NGS). This approach combines FusionPlex® and VariantPlex® panels to characterize gene fusions, copy number variations (CNVs) and other variants from a single sample.
Archer® Solid Tumor tests provide a targeted sequencing approach that includes commercial RUO products and services for therapy optimization and cancer monitoring. In addition, we are developing products and services for regulated clinical diagnostics. This approach combines FusionPlex®, VariantPlex®, LiquidPlex™ and Immunoverse™, collectively referred to as ArcherPlex™ to characterize gene fusions, CNVs and other variants from a single, low-input FFPE sample and liquid biopsy.
You are now leaving archerdx.com. Links to sites outside of ArcherDX are provided as a resource to the viewer. ArcherDX accepts no responsibility for the content of linked sites.
We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.